PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRalpha and LXRbeta with IC50 of 2.04 µM and 1.58 µM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models[1].